Amphastar Pharmaceuticals, Inc.

Valuation Analysis

About the Company

Amphastar Pharmaceuticals, Inc., a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. It offers BAQSIMI, a dry nasal spray used in an emergency for the treatment of severe hypoglycemia; Primatene MIST, an epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Glucagon for injection emergency kit; Enoxaparin, an injectable form of low molecular weight heparin for the prevention and treatment of deep vein thrombosis; and REXTOVY and Naloxone for opioid overdose. The company also provides Cortrosyn, a lyophilized power for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency; Amphadase

Amphastar Pharmaceuticals, Inc. Stock at a Glance

Amphastar Pharmaceuticals, Inc. (AMPH) is currently trading at $20.09 with a market capitalization of $885.8M. The trailing P/E ratio stands at 12.1x, with a forward P/E of 6.39x. The 52-week range spans from $16.65 to $31.26; the current price is 35.7% below the yearly high. Year-over-year revenue growth stands at +0.4%. The net profit margin stands at 11%.

💰 Dividend

Amphastar Pharmaceuticals, Inc. currently does not pay a dividend. The company typically reinvests its earnings into growth initiatives and product development.

📊 Analyst Rating

6 analysts rate Amphastar Pharmaceuticals, Inc. (AMPH) on consensus: Hold. The average price target is $22.83, implying +13.66% from the current price. Analyst price targets range from $19.00 to $30.00.

Amphastar Pharmaceuticals, Inc.: The Investment Case in Detail

Amphastar Pharmaceuticals, Inc. (AMPH) operates in the Healthcare — specifically Drug Manufacturers - Specialty & Generic — and is headquartered in United States. Below is a structured read of the investment case built directly from the latest fundamentals, valuation multiples, analyst positioning and smart-money flows. Each section translates raw numbers into the investment logic they imply, so you can decide whether the risk/reward fits your portfolio.

The Bull Case

Our valuation screen flags the stock as undervalued relative to its fundamentals — multiples are running below where the cash flow profile would normally justify.

The Bear Case

Revenue growth has slowed to just 0.4%, which is below nominal GDP — the business is no longer outgrowing the broader economy. Short interest sits at 17.78% of float — a meaningful contingent of professionals is positioned for the share to fall, which deserves attention even if their thesis may turn out to be wrong.

Valuation in Context

The EV/EBITDA multiple of 6.49x is below the historical equity-market average — strategic acquirers would find the cash-flow profile attractive at this level.

What to Watch Next

• The forward P/E of 6.39x is meaningfully below the trailing 12.1x — analysts expect earnings to step up; the next earnings release is the test.
• The price sits in the lower quartile of the 52-week range — value hunters often start scaling in around this zone if fundamentals hold.

Investment Thesis: Strengths & Weaknesses

Technical Snapshot

Price is below both the 50- and 200-day moving averages, with 50d below 200d — a bearish picture (death-cross alignment).

Risk Profile

The data points to relatively defensive market behavior, elevated short interest (17.78%).

Trading Data

Related Stocks in the Same Sector

Where can I buy Amphastar Pharmaceuticals, Inc.?

Compare top-rated brokers — low fees, trusted providers, fully regulated.